Stock Track | SELLAS Life Sciences Soars 5.21% Intraday on Investor Conference Announcements and Positive Growth Coverage

Stock Track05-14

SELLAS Life Sciences Group Inc. (NASDAQ: SLS) saw its stock price soar 5.21% during intraday trading on Thursday, driven by company news and positive analyst coverage highlighting its growth potential.

The biopharmaceutical company announced that its President and CEO, Angelos Stergiou, will participate in several upcoming investor conferences, including the 2026 Stifel Virtual Targeted Oncology Forum, A.G.P.'s Annual Virtual Healthcare Conference, and TD Cowen's 7th Annual Oncology Innovation Summit. These events, scheduled to begin the following week, are expected to increase visibility and investor engagement with the late-stage clinical company.

Concurrently, SELLAS was featured in a market analysis as a high-growth tech stock, with the report noting the company's development of SLS009 (tambiciclib), a potential best-in-class CDK9 inhibitor. The analysis highlighted preclinical data showing the drug's increased efficacy against acute myeloid leukemia, particularly in treatment-resistant models, and forecasted strong revenue growth for the company, significantly outpacing the broader market average.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1197905650?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-14 23:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1197905650","market":"hk","top_or_hot":-1,"title":"Stock Track | SELLAS Life Sciences Soars 5.21% Intraday on Investor Conference Announcements and Positive Growth Coverage","media":"Stock Track","content":"<p>SELLAS Life Sciences Group Inc. (NASDAQ: SLS) saw its stock price soar 5.21% during intraday trading on Thursday, driven by company news and positive analyst coverage highlighting its growth potential.</p><p>The biopharmaceutical company announced that its President and CEO, Angelos Stergiou, will participate in several upcoming investor conferences, including the 2026 Stifel Virtual Targeted Oncology Forum, A.G.P.'s Annual Virtual Healthcare Conference, and TD Cowen's 7th Annual Oncology Innovation Summit. These events, scheduled to begin the following week, are expected to increase visibility and investor engagement with the late-stage clinical company.</p><p>Concurrently, SELLAS was featured in a market analysis as a high-growth tech stock, with the report noting the company's development of SLS009 (tambiciclib), a potential best-in-class CDK9 inhibitor. The analysis highlighted preclinical data showing the drug's increased efficacy against acute myeloid leukemia, particularly in treatment-resistant models, and forecasted strong revenue growth for the company, significantly outpacing the broader market average.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | SELLAS Life Sciences Soars 5.21% Intraday on Investor Conference Announcements and Positive Growth Coverage</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | SELLAS Life Sciences Soars 5.21% Intraday on Investor Conference Announcements and Positive Growth Coverage\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-14 23:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SELLAS Life Sciences Group Inc. (NASDAQ: SLS) saw its stock price soar 5.21% during intraday trading on Thursday, driven by company news and positive analyst coverage highlighting its growth potential.</p><p>The biopharmaceutical company announced that its President and CEO, Angelos Stergiou, will participate in several upcoming investor conferences, including the 2026 Stifel Virtual Targeted Oncology Forum, A.G.P.'s Annual Virtual Healthcare Conference, and TD Cowen's 7th Annual Oncology Innovation Summit. These events, scheduled to begin the following week, are expected to increase visibility and investor engagement with the late-stage clinical company.</p><p>Concurrently, SELLAS was featured in a market analysis as a high-growth tech stock, with the report noting the company's development of SLS009 (tambiciclib), a potential best-in-class CDK9 inhibitor. The analysis highlighted preclinical data showing the drug's increased efficacy against acute myeloid leukemia, particularly in treatment-resistant models, and forecasted strong revenue growth for the company, significantly outpacing the broader market average.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SLS","symbol_name":"SELLAS Life Sciences Group Inc.","start_time":0,"source_url":"","article_id":"1197905650","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1197905650","pubTimestamp":1778773869,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"SELLAS Life Sciences Group Inc. (NASDAQ: SLS) saw its stock price soar 5.21% during intraday trading on Thursday, driven by company news and positive analyst coverage highlighting its growth...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SLS":"SELLAS Life Sciences Group Inc."},"translate_title":"个股赛道|SELLAS Life Sciences因投资者会议公告和正增长覆盖盘中飙升5.21%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SLS":1},"content_text":"SELLAS Life Sciences Group Inc. (NASDAQ: SLS) saw its stock price soar 5.21% during intraday trading on Thursday, driven by company news and positive analyst coverage highlighting its growth potential.The biopharmaceutical company announced that its President and CEO, Angelos Stergiou, will participate in several upcoming investor conferences, including the 2026 Stifel Virtual Targeted Oncology Forum, A.G.P.'s Annual Virtual Healthcare Conference, and TD Cowen's 7th Annual Oncology Innovation Summit. These events, scheduled to begin the following week, are expected to increase visibility and investor engagement with the late-stage clinical company.Concurrently, SELLAS was featured in a market analysis as a high-growth tech stock, with the report noting the company's development of SLS009 (tambiciclib), a potential best-in-class CDK9 inhibitor. The analysis highlighted preclinical data showing the drug's increased efficacy against acute myeloid leukemia, particularly in treatment-resistant models, and forecasted strong revenue growth for the company, significantly outpacing the broader market average.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.4","shortVersion":"4.42.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1197905650","isCrawlerRequest":true}